CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging margins.

CVS Health Corp. closed $34.74 short of its 52-week high ($80.75), which the company reached on March 28th.

Out of all of the special options we uncovered, 6 are puts, for a total amount of $241,558, and 4 are calls, for a total ...

CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and ...

In a report released today, Charles Rhyee from TD Cowen maintained a Hold rating on CVS Health (CVS – Research Report), with a price target of ...

CVS Health Corp. shares dipped below $50 on Thursday ... Separately, PBMs are being sued by the Federal Trade Commission. The industry is pushing back, saying the lawsuits are without merit ...

CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...

In September, the Federal Trade Commission sued the PBMs owned by CVS, UnitedHealth and Cigna, alleging they artificially raised prices on insulin drugs. CVS is a PBM through its CVS Caremark ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...